Announcement • Oct 27
Nasdaq Stock Market to Delist the American Depositary Shares of Molecular Data Inc On October 26, 2022, Nasdaq Stock Market announced that it will delist the American Depositary Shares of Molecular Data Inc. Molecular Data’s securities were suspended on September 7, 2022, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting become effective ten days after the Form 25 is filed. Board Change • Aug 02
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 25
Molecular Data Receives NASDAQ Notification Molecular Data Inc. announced that it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that to date, it has not regained compliance with the Rule 5250(c)(1). Since the Company is already before a Hearings Panel for its failure to comply with the $1.00 minimum bid price requirement set forth in Listing Rule 5550(a)(2),pursuant to Listing Rule 5810(d)(2), rather than submit a compliance plan for Staff's review, the Company is to address the matter before the Hearings Panel. Announcement • May 29
Molecular Data Inc. Receives NASDAQ Notification Regarding Minimum Bid Requirements Molecular Data Inc. announced that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that its minimum closing bid price per share for its ordinary shares had fallen below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On November 29, 2021, the Company was provided with an additional 180 calendar day compliance period, or until May 23, 2022, to demonstrate compliance. On May 24, 2022, the Company received notice from Nasdaq that it has not regained compliance with Listing Rule 5550(a)(2) and that its American Depository Shares ("ADS") would be delisted from the Capital Markets and a Form 25- NSE filed with the Securities and Exchange Commission (the "SEC") to remove the Company's securities from listing and registration on The Nasdaq Stock Market unless the Company requests a hearing for an appeal. On May 26, 2022, the Company submitted a hearing request to a Hearings Panel (the "Panel") for an appeal pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The hearing request will stay the suspension and delisting action pending the issuance of a written Panel decision. Announcement • May 21
Molecular Data Announces Receipt of Nasdaq Non-Compliance Letter On May 20, 2022, Molecular Data Inc. announced that on May 17, 2022, it received a Delinquency Compliance Plan Alert Letter (the "Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), because it has not timely filed its annual report on Form 20-F for the period ended December 31, 2021. In the Letter, Nasdaq stated that the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Company's Form 20-F's filing due date, or until November 14, 2022, to regain compliance. Announcement • May 03
Molecular Data Inc. announced delayed 20-F filing On 05/02/2022, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Board Change • Apr 27
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Dec 08
Molecular Data Inc. Adopts Blockchain to Enhance its Platform Molecular Data Inc. has upgraded its platform using Blockchain for its current chemical business. With properties of Blockchain including traceability and transparency, such an adoption can be applied in numerous processes from the front to back end in the current business to improve credibility. Also, the transactions efficiency and safety will be enhanced. Reported Earnings • Oct 07
First half 2021 earnings released: CN¥0.22 loss per share The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020). Announcement • Sep 24
Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million. Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million.
Security Name: Common Units
Security Type: Equity/Derivative Unit
Securities Offered: 23,390,000
Price\Range: $0.38
Discount Per Security: $0.0304
Security Name: Pre-Funded Units
Security Type: Equity/Derivative Unit
Securities Offered: 16,083,684
Price\Range: $0.3799
Discount Per Security: $0.030392
Transaction Features: Registered Direct Offering Announcement • Jul 15
Molecular Data Inc. announced that it expects to receive $1.9 million in funding from Yorkville Advisors Global LP Molecular Data Inc. announced that it has entered into a securities purchase agreement with returning investor, YA II PN, Ltd., a fund managed by Yorkville Advisors Global LP for a private placement of convertible debentures for gross proceeds of $1,900,000 on July 14, 2021. The convertible debentures bear interest of 5% per year. The securities are issued at a discount of 5%. The investor shall be entitled to convert any portion of the outstanding and unpaid conversion amount into fully paid and nonassessable ordinary Shares. The debenture will mature on July 14, 2022 unless earlier converted or redeemed. Upon conversion, the company will issue American depositary shares to the investor. The initial conversion price shall be the lower of $1.30 per share, or 88% of a reference price benchmarked against trading price of the company's shares. Each American depositary share represents three class A ordinary shares of the company. Announcement • May 04
Molecular Data Inc. announced delayed 20-F filing On 05/03/2021, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Apr 10
Molecular Data Inc. announced that it has received $7.5 million in funding Molecular Data Inc. (NasdaqCM:MKD) announced that it has raised up to $7.5 million in a round of funding from accredited investor on April 9, 2021. Announcement • Mar 11
Molecular Data Inc. Enters Supply Framework Agreement with Anhui Gujing Distillery Co., Ltd Molecular Data Inc. announced that it has entered into a supply framework agreement with Anhui Gujing Distillery Co. Ltd. ("Gujing"), one of the most important core enterprises in China's liquor market, as part of its efforts to expand presence in the food and beverage industry. Under the agreement, Molecular Data will become a key supplier for Gujing and its affiliated companies, including Anhui Runan Xinke Testing Technology Co. Ltd.("Runan Xinke") and Anhui Ruisi Weier Technology Co. Ltd. ("Ruisi Weier"), in the fields of chemical reagents, biological reagents, laboratory consumables, as well as related instruments and equipment. Molecular Data will source nearly 2 million stock-keeping units (SKUs) that Gujing requires from its 21 well-known domestic and foreign laboratory brands and suppliers. Molecular Data'sMKD Lab Supplies Mall is a data-driven one-stop laboratory supplies e-commerce service platform, which covers all categories of chemical reagents, biological reagents, laboratory consumables, and equipment. The mall serves scientific research institutions, hospitals, university laboratories, third-party testing units and production plants, providing procurement services that include all categories of reagents and intermediates. With a history of more than 1,800 years, Gujing Gongjiu is one of the eight most prestigious liquor brands in China, and has won the gold medal in the national spirits appraisal four times consecutively. Gujing's research capabilities in liquor are also industry leading. In accordance with the national standards of top laboratories, Gujing has established research and development centers, national post-doctoral research workstations, academic workstations, national food enterprise quality and safety testing technology demonstration centers and other scientific research platforms. Both affiliates of Gujing, Runan Xinke is a state-owned third-party testing institution that provides one-stop testing services from inspection to testing and technical services with various national certification; while Ruisi Weier has been striving for technology development related to biological fermentation engineering. The collaboration with Gujing is another milestone for Molecular Datato propel digitalization of the traditional industries and empower intelligent manufacturing in China. Molecular Data will continue to optimize supply chain services and upgrade the digital products, helping enterprises both from China and abroad to reduce costs and increase efficiency to spur the development of the industry. Is New 90 Day High Low • Feb 13
New 90-day high: US$1.87 The company is up 68% from its price of US$1.11 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 10.0% over the same period. Is New 90 Day High Low • Jan 16
New 90-day low: US$0.80 The company is down 28% from its price of US$1.12 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is flat over the same period. Announcement • Dec 30
Molecular Data Inc. Announces Cessation of Dongliang Chang as Member of the Audit Committee of the Board of Directors Molecular Data Inc. announced that Dr. Dongliang Chang ceases to serve as a member of the audit committee of the board of directors of the Company, effective immediately to ensure audit committee independence. Dr. Chang will continue to serve as the Chairman of Board of Directors. Is New 90 Day High Low • Dec 28
New 90-day low: US$0.85 The company is down 25% from its price of US$1.13 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 3.0% over the same period. Announcement • Dec 03
Molecular Data Inc. Announces Management Changes Molecular Data Inc. announced that the Company has appointed Mr. Steven Foo as the new chief financial officer, effective December 1, 2020. Mr. Zhaohong Li has tendered his resignation as chief financial officer, for personal reasons. Mr. Foo brings over 24 years of investment, financing experience as well as financial management and restructuring work experience in Asia. Previously, Mr. Foo served as a member of the board of directors and chief financial officer of SOS Health Rescue Services. Prior to that, Mr. Foo served as a member of the board of directors and chief financial officer of Hebron Technology. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in securities laws and regulations compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets. Is New 90 Day High Low • Dec 02
New 90-day low: US$1.04 The company is down 11% from its price of US$1.17 on 03 September 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is down 4.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: US$1.09 The company is down 62% from its price of US$2.87 on 17 July 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period. Announcement • Sep 29
Li Li to Step Down as Vice President of Molecular Data Inc., Effective September 29, 2020 Molecular Data Inc. announced that Mr. Li Li, co-founder and vice president of the Company, will step down from his current position for personal reasons, effective September 29, 2020, and will serve as the vice president of the strategy advisory committee of the Company. Is New 90 Day High Low • Sep 24
New 90-day low: US$1.11 The company is down 42% from its price of US$1.91 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period. 